Abstract Number: 2434 • ACR Convergence 2025
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Background/Purpose: We previously validated T Cell-bound C4d (TC4d), T Cell-bound IgG (TIgG), and T Cell-bound IgM (TIgM) biomarkers, demonstrating high sensitivity and specificity for differentiating…Abstract Number: 2451 • ACR Convergence 2025
Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
Background/Purpose: Photosensitivity lowers quality of life in patients with cutaneous lupus erythematosus (CLE) and puts patients with systemic lupus erythematosus (SLE) at risk of systemic…Abstract Number: 2469 • ACR Convergence 2025
Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus
Background/Purpose: Systemic glucocorticoid (GC) therapy is indispensable for treating active systemic lupus erythematosus (SLE) and lupus nephritis (LN), while contributing significantly to comorbidities and irreversible…Abstract Number: 2629 • ACR Convergence 2025
Predictors of 30-day Readmissions in Pregnant Patients with Systemic Lupus Erythematosus: The Impact of Social Determinants of Health.
Background/Purpose: Social Determinants of Health (SDOH) are increasingly recognized as significant contributors to adverse outcomes in pregnant patients with SLE. This study aims to evaluate…Abstract Number: 2696 • ACR Convergence 2025
Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Background/Purpose: Current evidence suggests that B cell depletion through CD19-directed chimeric antigen receptor T cell (CAR-T) therapies may offer promise in improving outcomes in severe…Abstract Number: 0119 • ACR Convergence 2025
Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…Abstract Number: 0367 • ACR Convergence 2025
Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus
Background/Purpose: Medication adherence poses a challenge for patients with SLE, especially younger patients, who often experience both more active disease and more intensive treatments than…Abstract Number: 0820 • ACR Convergence 2025
Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (JSLE). There is an urgent need to identify…Abstract Number: 0601 • ACR Convergence 2025
Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is an underrecognized neuroradiologic complication of SLE, characterized by acute neurological symptoms and vasogenic edema on neuroimaging. Its precipitating…Abstract Number: 0617 • ACR Convergence 2025
Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
Background/Purpose: Key features in the pathophysiology of SLE include cytokine dysregulation and autoantibody production. Traditional autoantibody testing in SLE is primarily limited to intracellular antigens…Abstract Number: 0635 • ACR Convergence 2025
Comparison of the SARC-F with Objective Measures of Sarcopenia in Women with Systemic Lupus Erythematosus
Background/Purpose: Sarcopenia, i.e., loss of skeletal muscle mass and strength, has been associated with multiple adverse health outcomes, including mortality. We have previously demonstrated associations…Abstract Number: 0659 • ACR Convergence 2025
Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
Background/Purpose: Human papillomavirus (HPV) is responsible for 99.7% of cervical neoplasms and is the fourth most common cancer among women worldwide. Patients with systemic lupus…Abstract Number: 0923 • ACR Convergence 2025
Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
Background/Purpose: Viral infections and major histocompatibility complex class II (MHC II) are both implicated in the genesis of systemic lupus erythematosus (SLE), but a mechanistic…Abstract Number: 0953 • ACR Convergence 2025
NMDAR Autoantibody-Induced Neuronal Damage in the Amygdala Mediates Mood and Anxiety Disorders in a Model of Neuropsychiatric Lupus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease characterized by aberrant production of autoantibodies and chronic inflammation. Up to 80% of individuals with…Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 181
- Next Page »